Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) of the Company

CSD/BSE&NSE/AR 2025-26 Date: July 30, 2026 To To Listing Department Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) Ref: Disclosure under Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the above subject, please find enclosed herewith the Notice of the 37th Annual General Meeting (AGM) of shareholders of the Company and the Annual Report for the Financial Year 2025-26, for the AGM scheduled to be held on Tuesday, August 25, 2026 at 11:30 a.m. (IST), through Video Conference (VC) / Other Audio Visual Means (OAVM). The Annual Report containing Notice of the AGM are also available on the Company’s website at: http://www.suven.com/annualreports.aspx The schedule of the remote e-voting is set out below: Cut-off date for e-voting Tuesday, August 18, 2026 E-voting start date and time Friday, August 21, 2026 at 9:00 a.m. IST E-voting end date and time Monday, August 24, 2026 at 5:00 p.m. IST This is for your information and record. Thanking you. For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary Encl.: As above Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: investorservices@suven.com website: www.suven.com On the Cusp SUVEN LIFE SCIENCES LIMITED 37TH ANNUAL REPORT 2025-26 paradox OUR RESULTS LOOK DIFFERENT, ...AND PUZZLING! INSIGNIFICANT INCREASED WIDENED REVENUE GROWTH R&D INVESTMENT NET LOSS (H CRORE) (H CRORE) (H CRORE) 17.55 21.05 172.43 291.62 160.75 276.34 Document milestones 01-22Corporate Overview 02On the cusp 09Our lead clinical-stage assets Our lead research-stage assets Statement from the Chairman’s Desk FY25 FY26 FY25 FY26 FY25 FY26 23-105Statutory Reports Management Discussion & Analysis 38Board’s Report Business Responsibility And Sustainability Report Report on Corporate Governance WE PUBLISH NO earnings guidance. 107-221Financial Statements Standalone Financial Statements Consolidated Financial Statements WE PUBLISH OUR molecule status. 222Notice 243Corporate Information CORPORATE STATUTORY FINANCIAL SUVEN LIFE SCIENCES LIMITED ANNUAL REPORT 2025-26 OVERVIEW REPORTS STATEMENTS reveal architects The We are 24YEARS | MANY INVENTIONS | 5 MOLECULES IN CLINICAL PIPELINE Masupirdine Samelisant Ropanicant Usmarapride Tenaclidine Every molecule in our pipeline was We build, not just the molecules, this architecture forward every day chosen. Nothing was accidental. but the pipeline of patents in CNS across every molecule and every phase. SUVN-502 SUVN-G3031 SUVN-911 SUVN-D4010 SUVN-I6107 CNS was never an easy space to enter. inventions. This year, that same rigour showed itself Phase 3 study Global Phase 3 study Successfully completed Has completed Phase 1. Has completed Phase It remains the hardest. We chose it Since inception, our portfolio exceeds in a different form. Ropanicant, molecule for Agitation and initiated in April 2026 Phase 2b Clinical Phase 2 clinical trial will 1. Preparing for Phase 2 deliberately, more than 2 decades ago, 3,056 global product patents for 62 targeting Major Depressive Disorder Aggression in for EDS in Narcolepsy Proof-of-Concept Trial. be initiated Q3/4 2026 clinical trials fully aware of what that choice would inventions and many molecules in (MDD) crossed Phase 2b successfully. Alzheimer’s type Positive clinical data cost us in time, in capital, in patience. pipeline and more to come. Samelisant, molecule targeting dementias in USA and support advancement We designed this pipeline the way an narcolepsy entered Phase 3. Tenaclidine Europe. Interim analysis into Phase 3 This design discipline extends to the architect designs a building: knowing completed Phase 1 successfully. conducted successfully, development for Major hands that build it. A team of 142, of the load it must bear, long before the with no safety issues. Depressive Disorder whom 102 are research scientists, carries walls go up. 95% enrolment completed. Topline data is expected in Q1/ Q2 2027 THAT IS NOT HOPE. WE ARE NOT BUILDING FOR THE NEXT QUARTER. THAT IS ON SCHEDULE. WE ARE WE ARE BUILDING FOR THE on the cusp. next generation. 02 03 CORPORATE STATUTORY FINANCIAL SUVEN LIFE SCIENCES LIMITED ANNUAL REPORT 2025-26 OVERVIEW REPORTS STATEMENTS witnesses We are We are watching science become We designed this molecule. We This is not an abstraction. Agitation medicine in real time. took it from a compound on a and aggression affects an estimated Phase 3 is not a concept in a slide deck. bench to a drug in a global pivotal 40-50% of people living with Alzheimer’s It is happening right now, in clinical sites trial spanning many countries. disease and difficult to manage at across the U.S. and Europe. Patients What began as a hypothesis home. A molecule with a non-sedating living with agitation associated with mechanism of action, tested against this about a 5-HT6 receptor is now a Alzheimer’s disease are being assessed, specific suffering, is not a line item. It is data point in a patient’s chart, dosed with Masupirdine and monitored. a bet on dignity, placed 2 decades ago, Masupirdine, a molecule we have carried somewhere, today. now approaching its final path. Patient enrolment is expected to be since its earliest nonclinical days, is now completed by the end of Q3/2026. in its final examination, crossing 95% of Expecting data release in Q1/Q2-2027. total patient enrolment in agitation and aggression study in Alzheimer Dementia. WE DO NOT SIMPLY RUN TRIALS. WE DO OUR BEST FOR PATIENT SAFETY AND STAND AT THE EDGE TO wait for the outcome. unwavering We are Failure has visited us before. It did Ropanicant carries that same resolve We do not measure our resolve not change our direction. forward. In its Phase 2b proof-of-concept in quarters. We measure it in Years ago, SUVN-502 did not cross the study, it showed a statistically significant decades, against molecules that endpoint in one of our Phase 2 trials and clinically meaningful improvement refuse to be rushed. for Alzheimer’s disease, despite over a in depressive symptoms, with clinician- About 300 million people worldwide decade of disciplined effort. We did not reported outcomes supporting the live with major depressive disorder and retreat. We repositioned its potential finding. It was built to address what by some estimates, roughly one in three for a different indication based on post current antidepressants cannot: That is , of them do not respond adequately to hoc analysis and kept moving because, no sedation, no withdrawal symptoms, existing treatment. This is the population in drug discovery, the chances of failure no sexual dysfunction, no abuse Ropanicant was designed for. If the data are always greater than the chances liability, no black box warning but with confirms what we believe, it will not of success, in other words it is 0 or 1 a a pro-cognitive effect. Now the Phase 3 just be a result. It will be a vindication of binary outcome. We knew this when we study for Major Depressive Disorder on every year we refused to walk away. chose this path. the cusp. WE HAVE NEVER DOUBTED ABOUT WHICH MOLECULE WOULD CARRY US FORWARD. WE HAVE NEVER BEEN WRONG ABOUT WHETHER TO keep going. 04 05 CORPORATE STATUTORY FINANCIAL SUVEN LIFE SCIENCES LIMITED ANNUAL REPORT 2025-26 OVERVIEW REPORTS STATEMENTS Readiness is not arrogance. It is We have secured the capital: H857 crore A new R&D centre in Genome the quiet confidence that comes raised through convertible warrants, Valley. Wree arae dy from having done the work. fully subscribed the moment we asked, We have relocated [Showing first 8,000 characters — download PDF for full document]